{
    "ticker": "SGPYY",
    "name": "Sangamo Therapeutics, Inc.",
    "description": "Sangamo Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on the development of transformative genomic therapies for patients with serious diseases. Founded in 1995 and headquartered in Richmond, California, Sangamo is a pioneer in gene editing and gene therapy technologies. The company has developed a proprietary technology platform based on its zinc finger protein (ZFP) technology, which allows for precise editing of genes to treat genetic diseases, cancer, and other serious health conditions. Sangamo's lead programs include treatments for hemophilia, sickle cell disease, and other genetic disorders. The company collaborates with leading pharmaceutical companies to advance its innovative therapies and has built a robust pipeline of product candidates, striving to deliver meaningful benefits to patients. With a commitment to scientific excellence and patient-centric approaches, Sangamo aims to revolutionize the treatment landscape for genetic diseases and contribute to the advancement of gene therapy as a mainstream medical option.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Richmond, California, USA",
    "founded": "1995",
    "website": "https://www.sangamo.com",
    "ceo": "Sandy Macrae",
    "social_media": {
        "twitter": "https://twitter.com/SangamoTX",
        "linkedin": "https://www.linkedin.com/company/sangamo-therapeutics/"
    },
    "investor_relations": "https://investors.sangamo.com",
    "key_executives": [
        {
            "name": "Sandy Macrae",
            "position": "CEO"
        },
        {
            "name": "Kathy High",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "SB-525 for Hemophilia A",
                "ST-400 for Sickle Cell Disease"
            ]
        },
        {
            "category": "Gene Editing",
            "products": [
                "ZFP Therapeutics"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sangamo Therapeutics, Inc. | Genomic Therapies for Serious Diseases",
        "meta_description": "Explore Sangamo Therapeutics, Inc., a leader in genomic therapies aimed at treating serious diseases through innovative gene editing and gene therapy approaches.",
        "keywords": [
            "Sangamo",
            "Gene Therapy",
            "Gene Editing",
            "Biotechnology",
            "Hemophilia",
            "Sickle Cell Disease"
        ]
    },
    "faq": [
        {
            "question": "What is Sangamo Therapeutics known for?",
            "answer": "Sangamo Therapeutics is known for its innovative genomic therapies, specifically in gene editing and gene therapy for serious diseases."
        },
        {
            "question": "Who is the CEO of Sangamo Therapeutics?",
            "answer": "Sandy Macrae is the CEO of Sangamo Therapeutics, Inc."
        },
        {
            "question": "Where is Sangamo headquartered?",
            "answer": "Sangamo is headquartered in Richmond, California, USA."
        },
        {
            "question": "What are Sangamo's main products?",
            "answer": "Sangamo's main products include SB-525 for Hemophilia A and ST-400 for Sickle Cell Disease, among others."
        },
        {
            "question": "When was Sangamo founded?",
            "answer": "Sangamo was founded in 1995."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "GILD"
    ]
}